Debates in AML: 7+3 Is No Longer the Standard of Care

XV Eurasian Hematology-Oncology Congress - EHOC 2024

T. Kadia

Secondary AML: Best Therapy Options

Weill Cornell Medicine Oncology & Hematology

P. Desai

ESMO 2024 Summary: IDH Mutated AML - Diagnostic and Treatment Paradi…

2024 ESMO Annual Meeting Insights Hub

T. Macarulla Mercade

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

Current & Emerging Therapies for AML and MDS

Indy Hematology Review

R. Komrokji

Prevention and Management of Post-SCT Relapse in Acute Leukemias

Vanderbilt University Medical Center (VUMC)

A. Jallouk

Managing Intensive-Chemotherapy Ineligible Patients With AML

Scripps Health

C. DiNardo

Current and Emerging Treatment Approaches for Patients With AML or M…

University of Miami Sylvester Comprehensive Cancer Center

S. Venugopal

Challenges in the Management of TP53-Mutated AML: Potential Strategi…

Talha Badar

Management of AML in Older Patients

XV Eurasian Hematology-Oncology Congress - EHOC 2024

F. Ravandi

Current Treatment Landscape in Myeloid Malignancies

Houston Methodist

S. Shah

Current Role of Maintenance Therapy in AML

Alice Mims

Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde

SOHO Brazil 2024

J. Lancet

Where I Use Azacitidine and Venetoclax in AML: Present and Future

SOHO Brazil 2024

J. Lancet

The Future Paradigm of HMA + Ven or Targeted Agents in AML: Sequenci…

Insights from 2023 ASH Annual Meeting

J. Watts

AML: Current Treatment Landscape and Key Recent Updates

UChicago Medicine

A. Patel

Experts Discuss the Use of Targeted Therapies in AML

MyCancerHaven

R. Vij, E. Wang

Using Transplant in Patients With p53 Mutant MDS or AML

Moffitt Cancer Center

H. Elmariah

A 50-Year Personal Perspective on the Treatment of AML

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

C. Schiffer

Oral Azacitidine in AML: Results from QUAZAR-AML-001 Trial

Jane Liesveld

State of the Art: Role of Maintenance Therapy in AML

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Z. Aziz

Key Updates in AML, MDS, & MF From ASH

Memorial Sloan Kettering Cancer Center

A. Goldberg

Is Post-HSCT Maintenance the SOC for AML?

Rush University Medical Center

M. Levis

The Gold Standard in the Use of FLT3 and IDH Inhibitors in AML

SOHO Brazil 2024

J. Lancet

The Role of Hypomethylating Agent Maintenance in AML

Yale Cancer Center

R. Shallis

EHA 2024 Insights: QUAZAR AML-001 - Oral Azacitidine Maintenance in …

Insights from 2024 EHA Annual Meeting

M. Teresa Voso

Importance of AML Maintenance Therapy

Gautam Borthakur

Optimal Use of Targeted Therapy for the Elderly or Unfit AML Patient

Moffitt Cancer Center

O. Chan